Tachyon Ventures

Founded in 2017, Tachyon Ventures is a venture capital firm based in Los Angeles. It invests in early-stage life sciences companies focusing on innovative areas such as immunotherapy, gene therapy, organ engineering, and stem cell medicine.

Neil Deramchi

Principal

Cristina Escoda

Managing Partner

19 past transactions

Axonis Therapeutics

Series A in 2024
Axonis Therapeutics is a biotechnology company focused on neurological disorders. It develops medicines targeting KCC2, a critical mediator of inhibition within the brain, using a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine. The company aims to improve lives by treating conditions such as epilepsy and pain.

EnClear Therapies

Venture Round in 2024
EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, that specializes in developing device-based therapies for neurodegenerative diseases. The company focuses on the delivery and monitoring of cerebrospinal fluid (CSF) and employs a proprietary therapeutic platform designed to remove toxic proteins from the CSF. EnClear's initial products are aimed at enhancing the quality of life for patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, EnClear Therapies is dedicated to advancing treatments that can halt disease progression and extend patient lives.

Altay Therapeutics

Seed Round in 2022
Founded in 2019, Altay Therapeutics is a biotechnology company based in San Francisco, California. It focuses on discovering novel small molecule therapies to treat chronic inflammatory conditions and diseases, including fibrosis, NASH, liver cancer, rheumatoid arthritis, fibrotic diseases, ulcerative colitis, and other chronic indications.

Mammoth Biosciences

Series D in 2021
Mammoth Biosciences harnesses diverse CRISPR systems for various applications. It offers DETECTRâ„¢ for nucleic acid detection in diseases like cancer and infections, and CRISPR-Cas systems for therapeutic genome editing in immuno-oncology, autoimmune diseases, and liver disorders. Its solutions span healthcare, agriculture, environmental monitoring, biodefense, and other sectors.

Chameleon Biosciences

Seed Round in 2021
Chameleon Biosciences Inc. is a biotechnology company focused on developing Adeno Associated Virus (AAV) based gene therapies aimed at treating rare genetic diseases. Founded in 2017 and headquartered in San Anselmo, California, the company utilizes innovative gene delivery technology to effectively administer therapeutic proteins to targeted tissues while minimizing immune responses to both the delivery vector and the therapeutic agents. This approach enhances gene delivery efficiency, reduces the immunogenicity of treatments, and expands the potential applications for patients with genetic disorders. Chameleon Biosciences is dedicated to addressing the significant challenges posed by genetic diseases, particularly in children, and strives to provide effective treatment options that allow for multiple systemic dose administrations, ensuring that affected individuals receive personalized care as their conditions evolve.

DTx Pharma

Series B in 2021
DTx Pharma, LLC is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of fatty acid-conjugated peptide therapeutics. Founded in 2017, the company focuses on delivering RNA-based medicines to treat patients with rare and chronic diseases, including retinitis pigmentosa, Duchenne muscular dystrophy, and various central nervous system disorders. DTx Pharma's innovative delivery technology addresses challenges faced by previous-generation platforms, such as poor pharmacokinetics and limited cellular uptake, thereby enhancing the efficiency of nucleic acid drug delivery across diverse tissues and cell types. The company aims to establish RNA therapeutics as a leading option for personalized treatment in multiple therapeutic areas.

Totient

Seed Round in 2020
Totient Inc. is an AI-driven biotechnology company based in Cambridge, Massachusetts, founded in 2016. The company specializes in using advanced machine learning and immunoinformatics to analyze complex datasets in the field of drug discovery and development. It focuses on identifying novel tissue-specific antigens and reconstructing high-affinity antibody therapeutics from tissues impacted by cancer, autoimmune diseases, and infections. By leveraging its platform's unique capabilities, Totient aims to quickly and accurately identify potent antibody candidates suitable for a variety of therapeutic applications, including cell therapies and bispecific antibodies. This innovative approach positions the company to address significant medical challenges in multiple areas of healthcare.

TARA Biosystems

Series A in 2020
TARA Biosystems, Inc. is a biotechnology company that specializes in developing organ-on-a-chip technology for evaluating new therapies and drug compounds, particularly in the field of cardiac medicine. Founded in 2014 and based in the United States, the company produces predictive in vitro human cardiac tissue models derived from human stem cells. These models are matured to physiologically relevant adult-like levels, allowing for accurate measurement of cardiac functionality, including contractile force. TARA Biosystems focuses on enhancing drug discovery and safety assessment processes by providing high-fidelity solutions that enable faster and safer development of new medicines. By harnessing human biology and data, the company aims to transform cardiac drug discovery and improve patient health outcomes.

Quthero

Seed Round in 2020
Quthero is focused on developing innovative solutions for post-surgical scarring prevention through a patented gel technology. This gel is designed to restore moisture and mechanical properties of wounds, facilitating effective healing while minimizing scarring, redness, and bruising. By promoting full epithelial restoration, Quthero's products aim to accelerate the closure of skin wounds, thereby reducing the complications and risks associated with slow healing. Their approach targets both cosmetic and medical applications, providing a comprehensive solution for individuals undergoing skin procedures or surgeries.

EnClear Therapies

Series A in 2020
EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, that specializes in developing device-based therapies for neurodegenerative diseases. The company focuses on the delivery and monitoring of cerebrospinal fluid (CSF) and employs a proprietary therapeutic platform designed to remove toxic proteins from the CSF. EnClear's initial products are aimed at enhancing the quality of life for patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). Incorporated in 2018, EnClear Therapies is dedicated to advancing treatments that can halt disease progression and extend patient lives.

Scipher Medicine

Series B in 2020
Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Mammoth Biosciences

Series B in 2020
Mammoth Biosciences harnesses diverse CRISPR systems for various applications. It offers DETECTRâ„¢ for nucleic acid detection in diseases like cancer and infections, and CRISPR-Cas systems for therapeutic genome editing in immuno-oncology, autoimmune diseases, and liver disorders. Its solutions span healthcare, agriculture, environmental monitoring, biodefense, and other sectors.

DTx Pharma

Series A in 2020
DTx Pharma, LLC is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of fatty acid-conjugated peptide therapeutics. Founded in 2017, the company focuses on delivering RNA-based medicines to treat patients with rare and chronic diseases, including retinitis pigmentosa, Duchenne muscular dystrophy, and various central nervous system disorders. DTx Pharma's innovative delivery technology addresses challenges faced by previous-generation platforms, such as poor pharmacokinetics and limited cellular uptake, thereby enhancing the efficiency of nucleic acid drug delivery across diverse tissues and cell types. The company aims to establish RNA therapeutics as a leading option for personalized treatment in multiple therapeutic areas.

Peptilogics

Venture Round in 2019
Peptilogics, Inc. is a clinical-stage biotechnology company based in West Mifflin, Pennsylvania, founded in 2013. The company specializes in designing and developing novel peptide therapeutics aimed at addressing the urgent challenge of multidrug-resistant bacterial infections. Peptilogics utilizes a unique computational platform that enhances drug discovery by exploring new chemical design spaces while ensuring the biological viability and manufacturability of potential therapeutics. Their lead candidate, PLG0206, is a broad-spectrum anti-infective peptide that targets prosthetic joint infections and has received both FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation. Through its innovative eCAP (engineered cationic antibiotic peptide) platform, Peptilogics aims to provide effective treatment options against resistant bacteria and biofilms, ultimately improving patient outcomes and affordability in healthcare.

Forkhead BioTherapeutics

Seed Round in 2019
Forkhead BioTherapeutics Inc. is a biopharmaceutical company focused on developing innovative oral therapies for insulin-dependent diabetes. Founded in 2017 and based in New York, the company is working on Foxin, an oral agent designed to target and delete the FOXO1 protein. This mechanism aims to restore normal insulin production and regulate glucose metabolism, potentially transforming the management of diabetes. Forkhead BioTherapeutics harnesses the natural processes of cell conversion and regeneration to create therapies that significantly enhance patients' lives.

EpiBone

Seed Round in 2018
EpiBone is a biotechnology company specializing in regenerative medicine for bone repair. It uses patient-specific stem cells and 3D fabrication to create living, anatomically precise bone grafts. The company's lead product has completed Phase I/IIa clinical trials, with additional products focusing on cartilage repair under development.

Mammoth Biosciences

Series A in 2018
Mammoth Biosciences harnesses diverse CRISPR systems for various applications. It offers DETECTRâ„¢ for nucleic acid detection in diseases like cancer and infections, and CRISPR-Cas systems for therapeutic genome editing in immuno-oncology, autoimmune diseases, and liver disorders. Its solutions span healthcare, agriculture, environmental monitoring, biodefense, and other sectors.

Xpense

Angel Round in 2018
Xpense is a blockchain-based company focused on developing technology to record consumption and behavior data. By utilizing distributed storage applications, Xpense creates a secure data management chain that ensures the integrity of records related to consumer behavior. This innovative approach allows retailers to access detailed consumption profiles of nearby individuals, enabling them to deliver targeted marketing information effectively. The company's commitment to preventing data alteration or falsification enhances the reliability of the insights generated, supporting businesses in making informed marketing decisions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.